Hikma Pharmaceuticals PLC (LON:HIK)

Market Cap	4.27B
Revenue (ttm)	2.50B
Net Income (ttm)	286.76M
Shares Out	220.43M
EPS (ttm)	1.29
PE Ratio	15.08
Forward PE	11.12
Dividend	0.60 (3.08%)
Ex-Dividend Date	Mar 20, 2025

Volume	1,089,432
Average Volume	442,275
Open	1,936.00
Previous Close	1,964.00
Day's Range	1,925.00 - 1,953.00
52-Week Range	1,751.00 - 2,360.00
Beta	0.65
RSI	38.17
Earnings Date	Aug 7, 2025

About CTI BioPharma

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 9,500
• Stock Exchange: London Stock Exchange
• Ticker Symbol: HIK

Financial Performance

In 2024, Hikma Pharmaceuticals's revenue was $3.13 billion, an increase of 8.77% compared to the previous year's $2.88 billion. Earnings were $359.00 million, an increase of 88.95%.